A Phase 2 interventional study of AD109 and AD504 in OSA - Obstructive Sleep Apnea, sponsored by Apnimed. Completed at 25 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Apnimed · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Sleep Apnea, Obstructive by Apnimed — 1 open to participants now, 1 under way, 1 of them phase 3. Sleep Apnea, Obstructive · Apnimed.
Among the 13 studies in Sleep Apnea, Obstructive by Apnimed, this one is the 4th largest by enrollment, is one of 3 that started in 2021, is one of 9 in phase 2, and was the 7th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →1 of the 13 studies in Sleep Apnea, Obstructive by Apnimed is open now, in 2 countries. Recruiting first, the newest first:
Apnimed · Sites in United States, Canada
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 3
First in 2019; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 294 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 60 across the 13 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Apnimed is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 8 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Sleep Apnea, Obstructive by Apnimed, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2 randomized double-blind placebo-controlled parallel-arm dose finding study to compare fixed dose combinations of AD109 and AD504 to atomoxetine or placebo in Obstructive Sleep Apnea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Atomoxetine 75 mg/Aroxybutynin 5 mg tablet
Drug: AD109
Atomoxetine 75 mg/Aroxybutynin 2.5 mg tablet
Drug: AD109
Atomoxetine 75 mg tablet/Trazodone 100 mg capsule
Drug: AD504
Atomoxetine 75 mg tablet/Trazodone 50 mg capsule
Drug: AD504
Atomoxetine 75 mg tablet
Drug: Atomoxetine Hydrochloride
Atomoxetine 75 mg tablet/placebo capsule
Drug: Atomoxetine Hydrochloride
Drug: Placebo
Drug: Placebo
Oral administration at bedtime
Oral administration at bedtime
Oral administration at bedtime
Oral administration at bedtime
Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD109 Arms vs. Placebo
Change in AHI4 (apnea-hypopnea index, 4% oxygen desaturation criterion; average respiratory events per hour of sleep) measured by in-lab polysomnography. Baseline was the mean of two pre-treatment PSG nights (Visits 2 and 3). Change from baseline was assessed at treatment PSG nights at approximately Day 21 (Visit 5) and Day 28 (Visit 6), modeled as repeated measures, with the reported value representing the model-based LS mean using equal (0.5/0.5) weighting between the Day 21 and Day 28 visits.
Time frame: Baseline (mean of PSG Visits 2 and 3) to Day 21 and Day 28 (PSG Visits 5 and 6)
Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD504 Arms vs. Placebo
Change in AHI4 (apnea-hypopnea index, 4% oxygen desaturation criterion; average respiratory events per hour of sleep) measured by in-lab polysomnography. Baseline was the mean of two pre-treatment PSG nights (Visits 2 and 3). Change from baseline was assessed at treatment PSG nights at approximately Day 21 (Visit 5) and Day 28 (Visit 6), modeled as repeated measures, with the reported value representing the model-based LS mean using equal (0.5/0.5) weighting between the Day 21 and Day 28 visits.
Time frame: Baseline (mean of PSG Visits 2 and 3) to Day 21 and Day 28 (PSG Visits 5 and 6)
Change in Apnea-Hypopnea Index (AHI4) From Baseline: Atomoxetine vs. Placebo
Change in AHI4 (apnea-hypopnea index, 4% oxygen desaturation criterion; average respiratory events per hour of sleep) measured by in-lab polysomnography. Baseline was the mean of two pre-treatment PSG nights (Visits 2 and 3). Change from baseline was assessed at treatment PSG nights at approximately Day 21 (Visit 5) and Day 28 (Visit 6), modeled as repeated measures, with the reported value representing the model-based LS mean using equal (0.5/0.5) weighting between the Day 21 and Day 28 visits.
Time frame: Baseline (mean of PSG Visits 2 and 3) to Day 21 and Day 28 (PSG Visits 5 and 6)
| Milestone | AD109 75/5mg | AD109 75/2.5mg | AD504 75/100mg | AD504 75/50mg | Atomoxetine 75mg | Placebo |
|---|---|---|---|---|---|---|
| Started | 41 | 42 | 43 | 40 | 64 | 64 |
| Completed | 35 | 33 | 38 | 38 | 49 | 59 |
| Not completed | 6 | 9 | 5 | 2 | 15 | 5 |
| Withdrew: Adverse event | 5 | 5 | 3 | 1 | 12 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 2 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other/unknown | 0 | 1 | 1 | 0 | 1 | 1 |
Change in AHI4 (apnea-hypopnea index, 4% oxygen desaturation criterion; average respiratory events per hour of sleep) measured by in-lab polysomnography. Baseline was the mean of two pre-treatment PSG nights (Visits 2 and 3). Change from baseline was assessed at treatment PSG nights at approximately Day 21 (Visit 5) and Day 28 (Visit 6), modeled as repeated measures, with the reported value representing the model-based LS mean using equal (0.5/0.5) weighting between the Day 21 and Day 28 visits.
| events/hr | AD109 Combined Dose Arms | AD109 75/5mg | AD109 75/2.5mg | Placebo |
|---|---|---|---|---|
| Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD109 Arms vs. Placebo | -7.38 (-9.53 to -5.23) | -7.40 (-10.41 to -4.38) | -7.37 (-10.44 to -4.30) | -0.21 (-2.49 to 2.07) |
Change in AHI4 (apnea-hypopnea index, 4% oxygen desaturation criterion; average respiratory events per hour of sleep) measured by in-lab polysomnography. Baseline was the mean of two pre-treatment PSG nights (Visits 2 and 3). Change from baseline was assessed at treatment PSG nights at approximately Day 21 (Visit 5) and Day 28 (Visit 6), modeled as repeated measures, with the reported value representing the model-based LS mean using equal (0.5/0.5) weighting between the Day 21 and Day 28 visits.
| events/hr | AD504 Combined Dose Arms | AD504 75/100mg | AD504 75/50mg | Placebo |
|---|---|---|---|---|
| Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD504 Arms vs. Placebo | -8.02 (-9.98 to -6.05) | -8.53 (-11.31 to -5.74) | -7.50 (-10.29 to -4.72) | -0.33 (-2.52 to 1.86) |
Change in AHI4 (apnea-hypopnea index, 4% oxygen desaturation criterion; average respiratory events per hour of sleep) measured by in-lab polysomnography. Baseline was the mean of two pre-treatment PSG nights (Visits 2 and 3). Change from baseline was assessed at treatment PSG nights at approximately Day 21 (Visit 5) and Day 28 (Visit 6), modeled as repeated measures, with the reported value representing the model-based LS mean using equal (0.5/0.5) weighting between the Day 21 and Day 28 visits.
| events/hr | Atomoxetine 75mg | Placebo |
|---|---|---|
| Change in Apnea-Hypopnea Index (AHI4) From Baseline: Atomoxetine vs. Placebo | -5.40 (-7.93 to -2.87) | -0.21 (-2.49 to 2.07) |
Collected over from randomization until end of study visit, up to 6 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AD109 75/5mg | 0/41 (0%) | 0/41 (0%) | 32/41 (78%) |
| AD109 75/2.5mg | 0/42 (0%) | 0/42 (0%) | 26/42 (61.9%) |
| AD504 75/100mg | 0/43 (0%) | 0/43 (0%) | 33/43 (76.7%) |
| AD504 75/50mg | 0/40 (0%) | 0/40 (0%) | 24/40 (60%) |
| Atomoxetine 75mg | 0/63 (0%) | 0/63 (0%) | 51/63 (81%) |
| Placebo | 0/63 (0%) | 0/63 (0%) | 25/63 (39.7%) |
| Event | AD109 75/5mg | AD109 75/2.5mg | AD504 75/100mg | AD504 75/50mg | Atomoxetine 75mg | Placebo |
|---|---|---|---|---|---|---|
| Dry MouthGastrointestinal disorders | 24/41 | 10/42 | 18/43 | 12/40 | 20/63 | 10/63 |
| Middle InsomniaPsychiatric disorders | 4/41 | 8/42 | 2/43 | 1/40 | 13/63 | 1/63 |
| ConstipationGastrointestinal disorders | 5/41 | 0/42 | 7/43 | 3/40 | 2/63 | 2/63 |
| NauseaGastrointestinal disorders | 4/41 | 5/42 | 3/43 | 3/40 | 4/63 | 2/63 |
| Initial InsomniaPsychiatric disorders | 2/41 | 3/42 | 1/43 | 1/40 | 7/63 | 1/63 |
| Urinary hesitationRenal and urinary disorders | 4/41 | 0/42 | 2/43 | 1/40 | 5/63 | 0/63 |
| Decreased appetiteMetabolism and nutrition disorders | 4/41 | 2/42 | 1/43 | 0/40 | 5/63 | 1/63 |
| InsomniaPsychiatric disorders | 3/41 | 0/42 | 0/43 | 1/40 | 3/63 | 0/63 |
| Feeling jitteryGeneral disorders | 3/41 | 2/42 | 1/43 | 0/40 | 2/63 | 1/63 |
| SomnolenceNervous system disorders | 3/41 | 1/42 | 1/43 | 1/40 | 0/63 | 1/63 |
Safety Set population: all randomized participants who received at least one dose of study drug.
| Age, Categorical(Participants) | AD109 75/5mg | AD109 75/2.5mg | AD504 75/100mg | AD504 75/50mg | Atomoxetine 75mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 37 | 40 | 34 | 37 | 56 | 58 | 262 |
| >=65 years | 4 | 2 | 9 | 3 | 7 | 5 | 30 |
| Age, Continuous(years) | AD109 75/5mg | AD109 75/2.5mg | AD504 75/100mg | AD504 75/50mg | Atomoxetine 75mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 54.2 ± 9.24 | 51.5 ± 9.22 | 57.8 ± 8.20 | 53.9 ± 8.81 | 52.8 ± 10.95 | 54.9 ± 9.03 | 54.2 ± 9.49 |
| Sex: Female, Male(Participants) | AD109 75/5mg | AD109 75/2.5mg | AD504 75/100mg | AD504 75/50mg | Atomoxetine 75mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 19 | 17 | 22 | 14 | 22 | 27 | 121 |
| Male | 22 | 25 | 21 | 26 | 41 | 36 | 171 |
| Race (NIH/OMB)(Participants) | AD109 75/5mg | AD109 75/2.5mg | AD504 75/100mg | AD504 75/50mg | Atomoxetine 75mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Asian | 2 | 2 | 1 | 2 | 3 | 5 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 11 | 5 | 5 | 5 | 9 | 41 |
| White | 33 | 28 | 34 | 31 | 52 | 48 | 226 |
| More than one race | 0 | 1 | 2 | 0 | 1 | 0 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 2 | 2 | 1 | 5 |
| Ethnicity (NIH/OMB)(Participants) | AD109 75/5mg | AD109 75/2.5mg | AD504 75/100mg | AD504 75/50mg | Atomoxetine 75mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 8 | 5 | 8 | 12 | 11 | 53 |
| Not Hispanic or Latino | 32 | 34 | 38 | 32 | 51 | 52 | 239 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | AD109 75/5mg | AD109 75/2.5mg | AD504 75/100mg | AD504 75/50mg | Atomoxetine 75mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| United States | 41 | 42 | 43 | 40 | 63 | 63 | 292 |
| Body Mass Index (BMI)(kg/m2) | AD109 75/5mg | AD109 75/2.5mg | AD504 75/100mg | AD504 75/50mg | Atomoxetine 75mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 31.12 ± 4.085 | 33.43 ± 4.352 | 30.89 ± 3.999 | 32.68 ± 3.537 | 31.16 ± 4.716 | 31.17 ± 4.719 | 31.65 ± 4.389 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2021 to primary completion in Jul 2022, 7 months.
Results were first posted in Aug 2026, 4 years after primary completion. A results delay was requested in Nov 2022.
Of 47 phase 2 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 46. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AD109
Apnimed